Alka Dwivedi, Ph.D.
- Center for Cancer Research
- National Cancer Institute
Postdoctoral Fellow
RESEARCH SUMMARY
Alka Dwivedi received her Ph.D. degree from Indian Institute of Technology Bombay, India in 2021 in developing indigenous CD19 CAR T cell therapy for leukemia and lymphoma patients. Then in 2021, she joined Taylor lab as a postdoctoral fellow. Currently, she is working on developing novel strategies with CAR T for the treatment of AML and ALL.
News
Image
Dr. Dwivedi was featured as one of TIME's top 100 influential people in the health space (TIME100 Health 2024) for her work developing India's first approved CAR T-cell therapy: NexCAR19. The treatment is produced in India and is less costly than CAR T-cell therapies made in the US, making it more accessible to this population.